Overview

Price chart · mood · technical indicators

GH

Guardant Health Incstock Healthcare

Diagnostics & Research

$91.17117.43%Current Market Mood:Bullish

Market Mood

Price Range (1Y)

$36.36$120.74

Current: $91.17

Idea: EMA

1Y Return

+125.8%

Sharpe 3Y

0.98

Market Comparison

vs Healthcare Sector & Diagnostics & Research Industry

+117.43%

1Y Performance

Healthcare

Sector 1Y

Diagnostics & Research

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-3.320.0% YoY

Profit margin-42.4%HEALTHCARE

Market cap$11.61BLarge cap

Wall Street coverage

$128.33median target· current $19.10 (+571.9%)23 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 55.67
P/S (TTM): 11.83
EV/EBITDA: -5.40

Profitability & growth

ROE (TTM): -4584.0%
Operating margin: -42.9%
Revenue growth YoY: 39.4%
Dividend yield: —
Beta: 1.65

Last earnings

Feb 19, 2026 · Estimate $-0.78 · Reported $-0.50

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Guardant Health Inc

Company profile

Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood City, California.

Classification

Sector: Healthcare
Industry: Diagnostics & Research
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 3100 HANOVER STREET, PALO ALTO, CA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$11.61B

Shares outstanding$132.6M

52W high$120.74

52W low$36.36

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

GH

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Is Guardant Health (GH) Attractively Priced After Strong Multi Year Share Price Gains

Short Interest in Guardant Health, Inc. (NASDAQ:GH) Decreases By 15.0%

Director at Guardant Health (GH) exercises 154 RSUs and holds 19,362 shares

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Guardant Health, Inc. $GH Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Analysts Conflicted on These Healthcare Names: CareDx (CDNA), Biogen (BIIB) and Guardant Health (GH)

Guardant Health Inc. announces a multi-year strategic partnership with biopharmaceutical company Nuvalent

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Barclays Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $115

EBITDA per share of Guardant Health, Inc. – DUS:5GH

Guardant Health Inc. announces a multi-year strategic partnership with biopharmaceutical company Nuvalent

Guardant Health lines up three investor conference webcasts

Guggenheim Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $135

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health slides as FDA briefing raises questions tied to AstraZeneca camizestrant review

[ARS] Guardant Health, Inc. SEC Filing

Canaccord reiterates Guardant Health stock rating ahead of FDA meeting By Investing.com

Guardant Health Announces Resignation of Chief Medical Officer

CMO Craig Eagle to leave Guardant Health (NASDAQ: GH) May 8

About Guardant Health Inc

Classification

Company profile

GH

Market Comparison

GH Market Analysis

Overview

GH

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Is Guardant Health (GH) Attractively Priced After Strong Multi Year Share Price Gains

Short Interest in Guardant Health, Inc. (NASDAQ:GH) Decreases By 15.0%

Director at Guardant Health (GH) exercises 154 RSUs and holds 19,362 shares

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Guardant Health, Inc. $GH Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Analysts Conflicted on These Healthcare Names: CareDx (CDNA), Biogen (BIIB) and Guardant Health (GH)

Guardant Health Inc. announces a multi-year strategic partnership with biopharmaceutical company Nuvalent

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Barclays Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $115

EBITDA per share of Guardant Health, Inc. – DUS:5GH

Guardant Health Inc. announces a multi-year strategic partnership with biopharmaceutical company Nuvalent

Guardant Health lines up three investor conference webcasts

Guggenheim Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $135

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health slides as FDA briefing raises questions tied to AstraZeneca camizestrant review

[ARS] Guardant Health, Inc. SEC Filing

Canaccord reiterates Guardant Health stock rating ahead of FDA meeting By Investing.com

Guardant Health Announces Resignation of Chief Medical Officer

CMO Craig Eagle to leave Guardant Health (NASDAQ: GH) May 8

About Guardant Health Inc

Classification

Company profile

GH

Market Comparison